Abstract
Abstract
Background
Lung cancer screening (LCS) for former and current smokers requires that current smokers are counseled on tobacco treatment. In the USA, over 4 million former smokers are estimated to be eligible for LCS based on self-report for “not smoking now.” Tobacco use and exposure can be measured with the biomarker cotinine, a nicotine metabolite reflecting recent exposure.
Objective
To examine predictors of tobacco use and exposure among self-reported former smokers eligible for LCS.
Design
Cross-sectional study using the 2013–2018 National Health and Nutrition Examination Survey.
Participants
Former smokers eligible for LCS (n = 472).
Main Measures
Recent tobacco use was defined as reported tobacco use in the past 5 days or a cotinine level above the race/ethnic cut points for tobacco use. Recent tobacco exposure was measured among former smokers without recent tobacco use and defined as having a cotinine level above 0.05 ng/mL.
Key Results
One in five former smokers eligible for LCS, totaling 1,416,485 adults, had recent tobacco use (21.4%, 95% confidence interval (CI) 15.8%, 27.0%), with about a third each using cigarettes, e-cigarettes, or other tobacco products. Among former smokers without recent tobacco use, over half (53.0%, 95% CI: 44.6%, 61.4%) had cotinine levels indicating recent tobacco exposure. Certain subgroups had higher percentages for tobacco use or exposure, especially those having quit within the past 3 years or living with a household smoker.
Conclusions
Former smokers eligible for LCS should be asked about recent tobacco use and exposure and considered for cotinine testing. Nearly 1.5 million “former smokers” eligible for LCS may be current tobacco users who have been missed for counseling. The high percentage of “passive smokers” is at least double that of the general nonsmoking population. Counseling about the harms of tobacco use and exposure and resources is needed.
Funder
Health Resources and Services Administration
National Center for Advancing Translational Sciences
National Cancer Institute
University of California Davis Health
Tobacco-Related Disease Research Program
Publisher
Springer Science and Business Media LLC
Reference37 articles.
1. Krist AH, Davidson KW, Mangione CM, Barry MJ, Cabana M, Caughey AB, et al. Screening for lung cancer: US preventive services task force recommendation statement. JAMA. 2021;325(10):962-70. https://doi.org/10.1001/jama.2021.1117
2. Ma J, Ward EM, Smith R, Jemal A. Annual number of lung cancer deaths potentially avertable by screening in the United States. Cancer. 2013;119(7):1381-5.
3. Medicare Coverage of Screening for Lung Cancer with Low Dose Computed Tomography (LDCT). 2015. https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/Downloads/mm9246.pdf. .
4. Howard DH, Richards TB, Bach PB, Kegler MC, Berg CJ. Comorbidities, smoking status, and life expectancy among individuals eligible for lung cancer screening. Cancer. 2015;121(24):4341-7. https://doi.org/10.1002/cncr.29677
5. Li J, Chung S, Martinez MC, Luft HS. Smoking-cessation interventions after lung cancer screening guideline change. Am. J. Prev. Med. 2020;59(1):88-97. https://doi.org/10.1016/j.amepre.2020.01.031
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献